Why the study?
Does digoxin use affect mortality at 2 years in patients with rheumatic heart disease?
Does digoxin use affect mortality at 2 years in patients with rheumatic heart disease?
In patients with rheumatic heart disease, digoxin use is associated with higher mortality overall, largely driven by treatment bias, though it may lower mortality in the subgroup with both atrial fibrillation and heart failure.
Answers are grounded in this paper and cite their sources.
Residual association after weighting suggests confounding by indication; leaves open causal effects in rheumatic heart disease.
OBJECTIVE: Digoxin is widely used in patients with rheumatic heart disease (RHD) despite a lack of data on its impact on clinical outcomes. We aimed to determine the association of digoxin use on clinical outcomes in patients with RHD. METHODS: We performed a retrospective analysis of the association of digoxin use with mortality at 2 years in a large RHD registry. Secondary outcomes were recurrent heart failure (HF) and hospitalisation for any cause. We assessed associations using multivariable logistic regression in the entire cohort and in subgroups of patients with atrial fibrillation (AF) and HF. We also estimated average treatment effects from propensity-adjusted analyses using inverse probability treatment weighting. RESULTS: Information on digoxin use at baseline was available for 98.7% (3298/3343) of patients. In the overall population, digoxin was significantly associated with mortality (OR 1.63, 95% CI 1.30 to 2.04, p<0.0001) and recurrent HF (OR 1.48, 95% CI 1.07 to 2.04, p=0.019). On propensity-weighted analyses, this effect was markedly attenuated (OR 1.05, 95% CI 1.01 to 1.09, p=0.005). Patients in sinus rhythm without HF had a higher propensity-adjusted odds of death with digoxin use (OR 1.06, 95% CI 1.01 to 1.12, p=0.015), but those with both AF and HF had lower mortality (OR 0.88, 95% CI 0.80 to 0.98, p=0.019). CONCLUSION: Digoxin use is associated with higher mortality in patients with RHD, but this is greatly attenuated on propensity adjustment, indicating the presence of substantial treatment bias. The adjusted estimates may therefore not be reliable, and large randomised trials are needed to determine the true effect of digoxin in patients with RHD.
No takes yet. Share an insight, caveat, or question.
Karthikeyan et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: